OR WAIT 15 SECS
October 23, 2015.
The global therapeutics and prophylactics market for Clostridium difficile infections (CDIs) will expand more than fourfold from $356.3 million in 2014 to over $1.5 billion by 2024, representing a CAGR of 15.8%, according to research and consulting firm GlobalData.
The company’s report states that the increase, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, will be driven by the modest uptake of patent-protected, CDI-specific antibiotics and the arrival of novel non-antibiotic approaches to treat and prevent recurrent CDI.
GlobalData analyst Marc C. Hansel, Ph.D., said that GlobalData anticipates that Merck’s Dificid will be the antibiotic market leader due to its first-to-market status and uncertainty over whether the current pipeline antibacterials, such as Actelion’s cadazolid, Merck’s surotomycin, and Summit Therapeutics’ SMT19969, will provide improved clinical benefits in terms of higher initial cure rates and lower recurrence rates.
He added that prophylactic vaccines, led by Sanofi Pasteur’s ACAM-CDIFF, will also contribute to the increase in CDI treatment market over the forecast period, and GlobalData projects a modest uptake of vaccines once they are approved in the 7MM.